| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/14/2009 | CA2348871C Multiparticulate modified release composition |
| 04/14/2009 | CA2337797C Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 04/14/2009 | CA2335900C Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| 04/14/2009 | CA2333339C A method for making a self-expanding stent-graft |
| 04/14/2009 | CA2329004C Combination of insulin sensitizer with anorectic for treating or preventing diabetes |
| 04/14/2009 | CA2279198C Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| 04/14/2009 | CA2275858C Vitamin powders for beverage applications |
| 04/14/2009 | CA2269682C Improved pharmaceutical compositions |
| 04/14/2009 | CA2259657C Identification of a transforming fragment of herpes simplex type 2 and detection thereof in clinical specimens |
| 04/14/2009 | CA2256007C Substituted heterocyclic benzocycloalkenes and their use as analgesic |
| 04/14/2009 | CA2253211C Sulfonamide-substituted fused 5-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
| 04/14/2009 | CA2240256C Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 04/14/2009 | CA2237582C Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| 04/14/2009 | CA2232378C Aerosol compositions |
| 04/14/2009 | CA2231244C Anti-stress agents for aquatic animals |
| 04/14/2009 | CA2230819C Medicament comprising hgf gene |
| 04/14/2009 | CA2229351C Free-flowing dried particles |
| 04/14/2009 | CA2227891C Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations |
| 04/14/2009 | CA2221279C Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| 04/14/2009 | CA2192941C Sterol derivatives used for regulation of meiosis |
| 04/14/2009 | CA2170479C Benzothiophene compounds, intermediates, compositions, and methods |
| 04/14/2009 | CA2166204C Pharmaceutical compositions for sparingly soluble therapeutic agents |
| 04/14/2009 | CA2138533C Drugs that enhance synaptic responses mediated by ampa receptors |
| 04/09/2009 | WO2009046444A2 Formulation for intranasal administration of diazepam |
| 04/09/2009 | WO2009046436A1 Methods for inhibiting senescence of epithelial cells |
| 04/09/2009 | WO2009046416A1 Anilinopyrimidines as jak kinase inhibitors |
| 04/09/2009 | WO2009046398A2 Method for preparing stable hop powder |
| 04/09/2009 | WO2009046383A1 Quinolone analogs and methods related thereto |
| 04/09/2009 | WO2009046371A1 Methods of treating metabolic diseases |
| 04/09/2009 | WO2009046369A2 Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| 04/09/2009 | WO2009046338A1 Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
| 04/09/2009 | WO2009046323A1 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| 04/09/2009 | WO2009046322A2 Compositions and methods for treating neural anoxia and spreading depression |
| 04/09/2009 | WO2009046314A2 Moenomycin analogs, methods of synthesis, and uses thereof |
| 04/09/2009 | WO2009046294A2 Treatment of proliferative disorders using antibodies to psma |
| 04/09/2009 | WO2009046221A1 Clear filtered nutritional supplement beverage and filtration method |
| 04/09/2009 | WO2009046127A1 Dt-diaphorase-active agents for treatment of pediatric tumors |
| 04/09/2009 | WO2009046104A1 Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
| 04/09/2009 | WO2009046098A1 Novel cyclic boronate inhibitors of hcv replication |
| 04/09/2009 | WO2009046025A1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| 04/09/2009 | WO2009046006A1 Compositions and methods for altering alpha- and beta-tocotrienol content using multiple transgenes |
| 04/09/2009 | WO2009046004A1 Carboxamide gabaa alpha2 modulators |
| 04/09/2009 | WO2009045999A1 Naphthalene isoxazoline compounds for control of invertebrate pests |
| 04/09/2009 | WO2009045992A2 C-met protein kinase inhibitors |
| 04/09/2009 | WO2009045985A1 Treatment of drug-induced nausea with opioid antagonists |
| 04/09/2009 | WO2009045975A1 Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase |
| 04/09/2009 | WO2009045951A1 Anti-bacterial pyrocatechols and related methods |
| 04/09/2009 | WO2009045908A2 A method for screening of prostaglandin compounds comprising an optimal formulation for the enhancement of hair growth and the stimulation of follicular anagen and formulations resulting therefrom |
| 04/09/2009 | WO2009045900A2 Methods for treating or preventing diseases associated with low bone mass |
| 04/09/2009 | WO2009045837A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| 04/09/2009 | WO2009045831A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| 04/09/2009 | WO2009045830A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| 04/09/2009 | WO2009045753A1 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 04/09/2009 | WO2009045735A2 Method for stabilizing quercetin |
| 04/09/2009 | WO2009045706A1 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
| 04/09/2009 | WO2009045700A2 5-lipoxygenase-activating protein (flap) inhibitors |
| 04/09/2009 | WO2009045655A2 Compositions containing purine nucleosides and manganese and their uses |
| 04/09/2009 | WO2009045603A1 Concentrated aqueous azalide formulations |
| 04/09/2009 | WO2009045555A1 Composition and method to modify sperm fertility and female gender ratio in mammals |
| 04/09/2009 | WO2009045543A1 Treatment of conditions related to shock |
| 04/09/2009 | WO2009045536A2 Receptor targeted oligonucleotides |
| 04/09/2009 | WO2009045535A2 Fluorine-18 derivative of dasatinib and uses thereof |
| 04/09/2009 | WO2009045520A2 Water-dispersible phytosterol-surfactant conglomerate particles |
| 04/09/2009 | WO2009045519A1 Modulators of muscarinic receptors |
| 04/09/2009 | WO2009045515A2 Antimicrobial and antiviral composition |
| 04/09/2009 | WO2009045505A2 Prohormones for increasing sexual performance |
| 04/09/2009 | WO2009045503A1 Method of treating polycystic kidney diseases with ceramide derivatives |
| 04/09/2009 | WO2009045488A2 Novel crystalline forms of armodafinil and preparation thereof |
| 04/09/2009 | WO2009045476A1 Pyrimidinedione derivatives |
| 04/09/2009 | WO2009045469A2 Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
| 04/09/2009 | WO2009045457A2 Tripartite rnai constructs |
| 04/09/2009 | WO2009045419A1 Novel azetidinones useful as inhibitors of elastase |
| 04/09/2009 | WO2009045397A1 Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases |
| 04/09/2009 | WO2009045386A1 N-substituted oxindoline derivatives as calcium channel blockers |
| 04/09/2009 | WO2009045385A1 N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors |
| 04/09/2009 | WO2009045383A1 Production of monatin stereoisomers |
| 04/09/2009 | WO2009045382A1 Substituted aryl sulfone derivatives as calcium channel blockers |
| 04/09/2009 | WO2009045381A1 N-substituted oxindoline derivatives as calcium channel blockers |
| 04/09/2009 | WO2009045370A2 Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| 04/09/2009 | WO2009045345A1 Metabolic degradation inhibitors for anti-hyperproliferative agents |
| 04/09/2009 | WO2009045337A1 Chemical sterilant for adult male dog population control, comprising a mineral gluconate and an amino acid |
| 04/09/2009 | WO2009045314A1 Gamma secretase modulators |
| 04/09/2009 | WO2009045313A2 Oxypiperidine derivatives as histamine receptor antagonists |
| 04/09/2009 | WO2009045311A1 Antifungal agents |
| 04/09/2009 | WO2009045308A2 Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression |
| 04/09/2009 | WO2009045291A2 Mast cell stabilizers in the treatment of obesity |
| 04/09/2009 | WO2009045224A1 Method for alleviating keratoconjunctivitis sicca |
| 04/09/2009 | WO2009045175A1 Pyrimidine substituted purine derivatives |
| 04/09/2009 | WO2009045174A1 2-morpholinylpurines as inhibitors of pi3k |
| 04/09/2009 | WO2009045172A1 Method and/or kit for determining response to muscarinic receptor antagonist treatment |
| 04/09/2009 | WO2009045145A1 Novel compounds for the treatment or alleviation of edema, and methods for their use |
| 04/09/2009 | WO2009045101A1 Use of diazoxide for suppressing the plasma insulin level in a mammal |
| 04/09/2009 | WO2009045083A2 Combination therapy for neuroprotection |
| 04/09/2009 | WO2009045054A2 A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof |
| 04/09/2009 | WO2009045053A2 A cancer sensitizer comprising chlorogenic acid |
| 04/09/2009 | WO2009045019A2 Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044919A1 Stable bicarbonate ion-containing drug solution |
| 04/09/2009 | WO2009044899A1 Nucleic acid capable of regulating the proliferation of cell |
| 04/09/2009 | WO2009044895A1 Composition inhibiting the expression of target gene |